Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075

International Journal of Infectious Diseases

Noel Kayange¹  Philip J. Palumbo²  William Clarke²  Vanessa Cummings²  Autumn Breaud²  Mariya Sivay²  Yinfeng Zhang²  Susan H. Eshleman²  Karen Dominguez³  Theodorus G.M. Sandfort⁴  Arthur Ogendo⁵  Ravindre Panchia⁶  Erica L. Hamilton⁷  Xu Guo⁸  Ying Q. Chen⁸ 

[1] Department of Internal Medicine, Johns Hopkins Project, College of Medicine, Malawi, Blantyre, Malawi;Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;Desmond Tutu HIV Centre, UCT Medical School, Cape Town, South Africa;HIV Center for Clinical and Behavioral Studies, Department of Psychiatry, Columbia University, New York, New York, USA;HIV Research Division, Kenya Medical Research Institute (KEMRI) CDC, Kisumu, Kenya;Perinatal HIV Research Unit, University of the Witwatersrand, Soweto HPTN CRS, Soweto, South Africa;Science Facilitation Department, FHI 360, Durham, North Carolina, USA;Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA;

关键词: HIV;    Antiretroviral drugs;    HIV drug resistance;    Viral suppression;    Men who have sex with men;    Transgender women;   

DOI  :  

来源: DOAJ

【 摘 要 】

Objectives: HPTN 075 enrolled men who have sex with men (MSM) and transgender women (TGW) in sub-Saharan Africa. Persons in HIV care or on antiretroviral treatment (ART) were not eligible to enroll. We evaluated antiretroviral (ARV) drug use, viral suppression, and drug resistance in this cohort over a 12-month follow-up period. Methods: Assessments included 64 participants with HIV (39 MSM, 24 TGW, and one gender not specified). ARV drugs were detected using a qualitative assay. Viral load (VL) and drug resistance testing were performed using commercial assays. Results: Over 12 months, the proportion of participants using ARV drugs increased from 28.1% to 59.4% and the proportion with VLs <400 copies/mL increased from 21.9% to 57.8%. The rate of ART failure (detection of drugs without viral suppression) was similar at screening and 12 months (12.0% and 11.1%, respectively) and was similar among MSM and TGW. Two participants developed HIV drug resistance during follow-up. Conclusions: Over 12 months, ARV drug use in the cohort more than doubled and viral suppression increased nearly threefold without a significant increase in ART failure or drug resistance. These results suggest that ART can be successfully scaled up for HIV prevention and treatment in this high-risk population.

【 授权许可】

Unknown